BRPI0408918A - formulação parenteral de ácido micofenólico, um sal ou pró-droga do mesmo - Google Patents

formulação parenteral de ácido micofenólico, um sal ou pró-droga do mesmo

Info

Publication number
BRPI0408918A
BRPI0408918A BRPI0408918-9A BRPI0408918A BRPI0408918A BR PI0408918 A BRPI0408918 A BR PI0408918A BR PI0408918 A BRPI0408918 A BR PI0408918A BR PI0408918 A BRPI0408918 A BR PI0408918A
Authority
BR
Brazil
Prior art keywords
salt
prodrug
mycophenolic acid
parenteral formulation
parenteral
Prior art date
Application number
BRPI0408918-9A
Other languages
English (en)
Inventor
Markus Ahlheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0408918A publication Critical patent/BRPI0408918A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçãO PARENTERAL DE áCIDO MICOFENóLICO, UM SAL OU PRó-DROGA DO MESMO". A presente invenção refere-se a uma composição farmacêutica na forma de pó ou de uma composição liofilizada para injeção, adequada para administração parenteral, compreendendo MPA, um sal ou pró-droga do mesmo.
BRPI0408918-9A 2003-04-01 2004-03-31 formulação parenteral de ácido micofenólico, um sal ou pró-droga do mesmo BRPI0408918A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307553.8A GB0307553D0 (en) 2003-04-01 2003-04-01 Organic compounds
PCT/EP2004/003423 WO2004087174A1 (en) 2003-04-01 2004-03-31 Parenteral formulation of mycophenolic acid, a salt or prodrug thereof

Publications (1)

Publication Number Publication Date
BRPI0408918A true BRPI0408918A (pt) 2006-03-28

Family

ID=9955996

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408918-9A BRPI0408918A (pt) 2003-04-01 2004-03-31 formulação parenteral de ácido micofenólico, um sal ou pró-droga do mesmo

Country Status (10)

Country Link
US (1) US20060189683A1 (pt)
EP (1) EP1615649A1 (pt)
JP (1) JP2006522052A (pt)
CN (1) CN100427097C (pt)
AU (1) AU2004226807B2 (pt)
BR (1) BRPI0408918A (pt)
CA (1) CA2518270A1 (pt)
GB (1) GB0307553D0 (pt)
MX (1) MXPA05010613A (pt)
WO (1) WO2004087174A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
MXPA06005659A (es) 2004-04-26 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
EP1740563A2 (en) 2004-04-27 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Mycophenolate mofetil impurity
US7439373B2 (en) 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
US20060235009A1 (en) 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
EP2310008A4 (en) * 2008-07-09 2014-03-05 Aspreva Internat Ltd MYCOPHENOLIC SODIUM ACID SOLUTIONS WITH PH SPECIFIC FOR THE TREATMENT OF OCULAR DISORDERS
WO2010134437A1 (ja) 2009-05-18 2010-11-25 Nishiyama Shuhei 仮想単一メモリストレージ上におけるメタ情報共有型分散データベース・システム
WO2011061761A2 (en) * 2009-11-17 2011-05-26 Matrix Laboratories Ltd Pharmaceutical composition for parenteral use
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
US9789080B2 (en) 2015-09-04 2017-10-17 Insite Vision Incorporated Ophthalmic formulations of mycophenolic acid
CN106727403A (zh) * 2017-01-03 2017-05-31 无锡福祈制药有限公司 一种麦考酚钠肠溶片及其制备方法
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
CN111632150A (zh) * 2020-06-10 2020-09-08 首都医科大学附属北京友谊医院 一种治疗肾病综合征的药物组合物
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法
CN116687913B (zh) * 2023-07-25 2024-01-26 北京中医药大学 霉酚酸在制备治疗食管癌药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
US4610977A (en) * 1985-04-08 1986-09-09 The University Of Tennessee Research Corporation N-alkyl and N-benzyl adriamycin derivatives
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
IL93618A0 (en) * 1989-03-06 1990-12-23 Lilly Co Eli Improved diluent formulation for daptomycin
JP2515162B2 (ja) * 1990-02-23 1996-07-10 富士写真フイルム株式会社 メチン化合物
AU3178293A (en) * 1992-11-24 1994-06-22 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JP3411038B2 (ja) * 1993-09-15 2003-05-26 シンテックス（ユー・エス・エイ）・インコーポレイテッド ミコフェノール酸モフェチルの結晶質無水物およびその静注用製剤
US5562808A (en) * 1993-09-21 1996-10-08 Pharm-Eco Laboratories, Inc. Method and apparatus for decontaminating a liquid surfactant of dioxane
EP1475091A1 (en) * 1993-10-01 2004-11-10 Roche Palo Alto LLC Mycophenolate mofetil - high dose oral suspensions
JPH0967358A (ja) * 1995-09-04 1997-03-11 Ajinomoto Co Inc ミコフェノール酸誘導体
WO2000015210A2 (en) * 1998-09-14 2000-03-23 Vertex Pharmaceuticals Incorporated Use of mycophenol acid and its derivatives for the treatment of virus diseases
DE60044717D1 (de) * 1999-05-10 2010-09-02 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
WO2001012214A2 (en) * 1999-08-13 2001-02-22 F. Hoffmann-La Roche Ag MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
JP2002241276A (ja) * 2001-02-16 2002-08-28 Kaken Pharmaceut Co Ltd ミコフェノール酸を含有する脂肪細胞分化抑制剤

Also Published As

Publication number Publication date
AU2004226807B2 (en) 2008-02-21
CA2518270A1 (en) 2004-10-14
EP1615649A1 (en) 2006-01-18
CN1767836A (zh) 2006-05-03
US20060189683A1 (en) 2006-08-24
MXPA05010613A (es) 2005-11-23
CN100427097C (zh) 2008-10-22
GB0307553D0 (en) 2003-05-07
AU2004226807A1 (en) 2004-10-14
WO2004087174A1 (en) 2004-10-14
JP2006522052A (ja) 2006-09-28

Similar Documents

Publication Publication Date Title
BRPI0408918A (pt) formulação parenteral de ácido micofenólico, um sal ou pró-droga do mesmo
BR0209489A (pt) Composições farmacêuticas
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
BRPI0417947A (pt) composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
UA96449C2 (en) Stable laquinimod preparations
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
MXPA05009933A (es) Composiciones que comprenden acidos grasos y aminoacidos.
TW200621317A (en) Pharmaceutical composition
BR9907647A (pt) Composições contendo composto orgânicos
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
CY1109457T1 (el) Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
BR112012017556A2 (pt) formulações de torta liofilizada
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
BRPI0514766A (pt) composições farmacêuticas
WO2008083678A3 (de) Isoflavon-peptid konjugate und deren verwendung
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
BRPI0508224A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto
MX2009003169A (es) Derivados de sulfonamida.
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.